Higher PAPP-A Values in Pregnant Women Complicated with Preeclampsia Than with Gestational Hypertension

Autores organización

• Ximena Carolina Romero Infante

  Autor

• 

  Edgar Antonio Ibañez Pinilla

  Autor

Autores

• Uriel M
• Rincón Franco S
• Rojas NA

Grupos de investigación

• Grupo de Investigación Medicina Materno Fetal y Ginecología - El Bosque MMFG-EB

  Investigador

  Ximena Carolina Romero Infante

• Medicina Comunitaria y Salud Colectiva

Resumen

The purpose of this study is to compare the levels of maternal serum pregnancy–associated plasma protein-A at the first trimester in pregnancies complicated by impaired placental diseases, such as preeclampsia (PE), intrauterine fetal growth restriction (IUGR), and gestational hypertension (GH), with those in pregnancies without the development of any of these outcomes to expand the knowledge of how this protein behaves in the different impaired placental diseases. This current work is an observational study based on a prospective cohort. Pregnancy-associated plasma protein-A was measured in 422 patients who had completed maternal-perinatal outcomes. Comparisons of pregnancy characteristics and the biomarker between outcome groups (PE, IUGR, gestational hypertension, and not impaired placental outcomes) were analyzed. PAPP-A MoM in the IUGR (0.8 IQR: 0.6–0.9) and GH groups (0.5 IQR: 0.3–1.4) compared to the PE group (1.06 IQR: 0.66–1.52) was significantly lower (p < 0.005). Pregnant women who developed early-onset PE (1.11 IQR 1.08–1.18) presented significant differences with the IUGR group (0.83 IQR: 0.59–0.98; p = 0.002) and those who developed preterm-PE (1.19 IQR: 0.66–1.58; p = 0.045). The results demonstrate that the levels of PAPP-A at first trimester in the sample of women who developed PE, and specially term-PE, were higher than those in women who developed GH or IUGR. The GH group had the lowest PAPP-A values in this sample of pregnant women. Research in a population with a high prevalence of preeclampsia is still lacking and deserves more extended studies to define if these patients could have different rates of PAPP-A. © 2023, The Author(s).

© 2023. The Author(s).

Keywords

• Biomarkers; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; Infant, Newborn; Placenta; Placenta Diseases; Pre-Eclampsia; Pregnancy; Pregnancy Trimester, First; Pregnancy-Associated Plasma Protein-A; Pregnant Women; Prospective Studies; pregnancy associated plasma protein A; biological marker; pregnancy associated plasma protein A; adult; Article; cohort analysis; comparative study; controlled study; diastolic blood pressure; female; fetus circulation; fetus outcome; first trimester pregnancy; gene expression; human; human tissue; informed consent; intrauterine growth retardation; major clinical study; maternal hypertension; maternal serum; mean arterial pressure; observational study; outcome assessment; preeclampsia; pregnant woman; prevalence; prophylaxis; prospective study; protein blood level; protein expression; smoking habit; systolic blood pressure; first trimester pregnancy; intrauterine growth retardation; maternal hypertension; metabolism; newborn; p